1832 Asset Management L.P. Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

1832 Asset Management L.P. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 472.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 456,335 shares of the medical research company’s stock after acquiring an additional 376,595 shares during the period. 1832 Asset Management L.P. owned approximately 0.25% of IQVIA worth $96,487,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter worth about $27,000. Rise Advisors LLC bought a new position in shares of IQVIA in the 1st quarter valued at about $31,000. Riverview Trust Co purchased a new position in IQVIA in the first quarter worth about $32,000. Finally, International Assets Investment Management LLC bought a new stake in IQVIA during the second quarter worth approximately $32,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.0 %

Shares of NYSE:IQV opened at $242.12 on Monday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $44.14 billion, a PE ratio of 33.08, a P/E/G ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The business’s fifty day simple moving average is $240.60 and its 200-day simple moving average is $233.94.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group began coverage on IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. Morgan Stanley lifted their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Evercore ISI increased their price objective on shares of IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.